CL2022003511A1 - Inhibidores de alk2 para el tratamiento de la anemia. - Google Patents

Inhibidores de alk2 para el tratamiento de la anemia.

Info

Publication number
CL2022003511A1
CL2022003511A1 CL2022003511A CL2022003511A CL2022003511A1 CL 2022003511 A1 CL2022003511 A1 CL 2022003511A1 CL 2022003511 A CL2022003511 A CL 2022003511A CL 2022003511 A CL2022003511 A CL 2022003511A CL 2022003511 A1 CL2022003511 A1 CL 2022003511A1
Authority
CL
Chile
Prior art keywords
anemia
treatment
alk2 inhibitors
alk2
inhibitors
Prior art date
Application number
CL2022003511A
Other languages
English (en)
Inventor
Yaoyu Chen
Francis Séguy
Ekaterine Asatiani
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of CL2022003511A1 publication Critical patent/CL2022003511A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

En el presente documento se proporcionan métodos para tratar la anemia en un sujeto que lo necesita, que comprenden administrar al sujeto una cantidad terapéuticamente eficaz de un inhibidor de ALK2.
CL2022003511A 2020-06-16 2022-12-09 Inhibidores de alk2 para el tratamiento de la anemia. CL2022003511A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063039742P 2020-06-16 2020-06-16
US202063056761P 2020-07-27 2020-07-27
US202163152516P 2021-02-23 2021-02-23

Publications (1)

Publication Number Publication Date
CL2022003511A1 true CL2022003511A1 (es) 2023-06-02

Family

ID=76845323

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2022003511A CL2022003511A1 (es) 2020-06-16 2022-12-09 Inhibidores de alk2 para el tratamiento de la anemia.
CL2023001952A CL2023001952A1 (es) 2020-06-16 2023-06-30 Inhibidores de alk2 para el tratamiento de la anemia (divisional).

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2023001952A CL2023001952A1 (es) 2020-06-16 2023-06-30 Inhibidores de alk2 para el tratamiento de la anemia (divisional).

Country Status (13)

Country Link
US (2) US11723899B2 (es)
EP (1) EP4164641A1 (es)
JP (1) JP2023530316A (es)
KR (1) KR20230025444A (es)
CN (1) CN115968289B (es)
AU (1) AU2021292484A1 (es)
CA (1) CA3187767A1 (es)
CL (2) CL2022003511A1 (es)
IL (1) IL298767A (es)
MX (1) MX2022015900A (es)
PH (1) PH12022553501A1 (es)
TW (1) TW202214239A (es)
WO (1) WO2021257532A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113366019B (zh) 2018-10-23 2024-08-27 科乐斯疗法公司 Alk2抗体及其使用方法
JP7717065B2 (ja) 2019-11-22 2025-08-01 インサイト コーポレーション Ａｌｋ２阻害剤及びｊａｋ２阻害剤を含む併用療法
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2021257532A1 (en) 2020-06-16 2021-12-23 Incyte Corporation Alk2 inhibitors for the treatment of anemia
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
US20250282877A1 (en) * 2021-05-11 2025-09-11 Keros Therapeutics, Inc. Methods of using alk2 and alk3 antibodies
WO2023198114A1 (zh) * 2022-04-13 2023-10-19 杭州邦顺制药有限公司 Alk2激酶抑制剂

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077290A (en) 1990-10-11 1991-12-31 Merck & Co., Inc. Morpholine derivatives compositions and use
TW530054B (en) 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
EP1501514B1 (en) 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
US20040067985A1 (en) 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
SE0203753D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
WO2004092727A2 (en) 2003-04-11 2004-10-28 Structural Genomix, Inc. Compound libraries and methods for drug discovery
AU2005247699A1 (en) 2004-05-27 2005-12-08 Pfizer Inc. Aminopyridine derivatives as selective dopamine D3 agonists
SA05260265A (ar) 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
BRPI0607913A2 (pt) 2005-04-08 2010-03-23 Eisai R&D Man Co Ltd agente terapÊutico para discinesia
WO2007011760A2 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
PE20071241A1 (es) 2006-01-17 2008-01-14 Schering Corp Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios
CA2658362A1 (en) 2006-06-29 2008-01-03 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors
CA2727174A1 (en) 2008-06-20 2010-01-21 Jiangao Song Aryl gpr119 agonists and uses thereof
US8987271B2 (en) 2010-12-22 2015-03-24 Eutropics Pharmaceuticals, Inc. 2,2′-biphenazine compounds and methods useful for treating disease
LT2714677T (lt) 2011-05-23 2018-12-10 Merck Patent Gmbh Piridino ir pirazino dariniai
CN108484449A (zh) 2011-09-09 2018-09-04 蓝瑟斯医学影像公司 用于合成和使用显像剂的组合物、方法和系统
JP6430383B2 (ja) 2012-09-28 2018-11-28 ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ 選択的ｂｍｐ阻害剤としての縮合複素環化合物
EP2964651A4 (en) 2013-03-04 2016-11-30 Brigham & Womens Hospital BMP HEMMER AND METHOD OF USE THEREOF
MX394360B (es) 2013-03-14 2025-03-24 Sumitomo Pharma Oncology Inc Inhibidores de jak2 y alk2 y metodos para su uso.
BR112016008632A8 (pt) 2013-10-21 2020-03-17 Merck Patent Gmbh compostos de heteroarila como inibidores de btk, seus usos, e composição farmacêutica
NZ734082A (en) 2015-01-20 2019-01-25 Boehringer Ingelheim Animal Health Usa Inc Anthelmintic compounds, compositions and method of using thereof
PE20181017A1 (es) 2015-08-31 2018-06-26 Dong A Socio Holdings Co Ltd Compuestos heteroarilo y su uso como farmacos terapeuticos
MX388518B (es) * 2016-07-20 2025-03-19 Novartis Ag Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2.
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
EP4041243A4 (en) 2019-09-27 2023-10-18 Disc Medicine, Inc. METHODS OF TREATMENT OF ANEMIA OF CHRONIC DISEASE
JP7717065B2 (ja) * 2019-11-22 2025-08-01 インサイト コーポレーション Ａｌｋ２阻害剤及びｊａｋ２阻害剤を含む併用療法
WO2021257532A1 (en) 2020-06-16 2021-12-23 Incyte Corporation Alk2 inhibitors for the treatment of anemia

Also Published As

Publication number Publication date
JP2023530316A (ja) 2023-07-14
AU2021292484A1 (en) 2023-01-19
PH12022553501A1 (en) 2024-04-22
US11723899B2 (en) 2023-08-15
MX2022015900A (es) 2023-01-24
CN115968289A (zh) 2023-04-14
US20210393605A1 (en) 2021-12-23
WO2021257532A1 (en) 2021-12-23
CA3187767A1 (en) 2021-12-23
CN115968289B (zh) 2025-09-30
KR20230025444A (ko) 2023-02-21
CL2023001952A1 (es) 2023-12-15
US12383541B2 (en) 2025-08-12
EP4164641A1 (en) 2023-04-19
TW202214239A (zh) 2022-04-16
IL298767A (en) 2023-02-01
US20230338352A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
CL2022003511A1 (es) Inhibidores de alk2 para el tratamiento de la anemia.
BR112023000687A2 (pt) Métodos e combinações de inibidores de kat6 para o tratamento de câncer
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
CL2021002966A1 (es) Combinación de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento del cancer.
MX2017010773A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte progamada 1 (pd-l1) para el tratamiento de cancer.
EA202190630A1 (ru) Способы комбинированной терапии
ECSP20069416A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
CR20190162A (es) Métodos para usar un anticuerpo biespecífico que reconoce el factor de coagulación ix y/o el factor de coagulación ix activado y el factor de coagulación x y/o el factor de coagulación x activado
BR112018073920A2 (pt) inibidores de pd-1/pd-l1 para tratamento de câncer".
MX2021008610A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
MX348941B (es) Medios y metodos para trata y/o prevenir el cancer dependiente del ligando natural de receptor de aril-hidrocarburo.
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
MX2024004216A (es) Terapias combinadas de inhibidores de kras g12d con inhibidores de la familia pan erbb.
UY33221A (es) MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
EA202190776A1 (ru) Комбинация маломолекулярных ингибиторов cd-47 с другими противораковыми агентами
MX387658B (es) Métodos para tratar y/o prevenir queratosis actínica.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
MX2021007565A (es) Composiciones y metodos para la terapia contra el cancer.
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
AR087902A1 (es) COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
MX2024003258A (es) Inhibidores de ribonucleotido reductasa (rnr) de sulfonamida ciclica y usos de los mismos.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2021006915A (es) Inhibidores de cxcr7 para el tratamiento de cancer.